Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Praluent

    regeneron headquarters

    Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma

    More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year

    - PMLiVE

    FDA unveils new voucher programme to accelerate drug review process

    The programme is designed to reduce the review time for companies supporting US national interests

    regeneron headquarters

    Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

    The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

    regeneron headquarters

    Regeneron to acquire human genetics company 23andMe for $256m

    The agreement comes two months after 23andMe filed for bankruptcy protection

    regeneron headquarters

    Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma

    More than 35,000 new cases of the blood cancer are diagnosed every year in Europe

    - PMLiVE

    FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

    The mosquito-borne viral disease has been reported across many popular travel destinations

    - PMLiVE

    Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

    The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

    regeneron headquarters

    Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer

    Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year

    - PMLiVE

    FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

    The company hopes the revised protocol will accelerate the development timeline of buntanetap

    - PMLiVE

    FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM

    Transthyretin amyloid cardiomyopathy affects up to 500,000 people worldwide

    - PMLiVE

    UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

    The inflammatory skin disease affects approximately one in every 100 people in the US

    - PMLiVE

    Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

    The serious adverse event reported was found to be unrelated to the vaccine

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links